CINECA IRIS Institutional Research Information System

CHIRICOZZI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.370
EU - Europa 1.654
AS - Asia 1.033
AF - Africa 178
SA - Sud America 30
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 9.275
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.230
CN - Cina 479
IT - Italia 412
GB - Regno Unito 305
BG - Bulgaria 298
SE - Svezia 243
SG - Singapore 189
VN - Vietnam 179
CI - Costa d'Avorio 145
CA - Canada 122
DE - Germania 80
FI - Finlandia 77
TR - Turchia 72
RU - Federazione Russa 44
AT - Austria 42
JP - Giappone 38
LT - Lituania 31
IE - Irlanda 26
IN - India 24
HK - Hong Kong 19
MX - Messico 18
ES - Italia 17
NL - Olanda 17
SN - Senegal 15
FR - Francia 13
ID - Indonesia 11
BR - Brasile 10
CH - Svizzera 9
BJ - Benin 8
HU - Ungheria 7
PL - Polonia 7
AR - Argentina 6
AU - Australia 6
EG - Egitto 6
KR - Corea 6
RO - Romania 5
BE - Belgio 4
CO - Colombia 4
GR - Grecia 4
PH - Filippine 4
UA - Ucraina 4
BO - Bolivia 3
EC - Ecuador 3
EU - Europa 3
MY - Malesia 3
PE - Perù 3
SA - Arabia Saudita 3
ZA - Sudafrica 3
IR - Iran 2
MT - Malta 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
CL - Cile 1
CZ - Repubblica Ceca 1
HR - Croazia 1
IL - Israele 1
JO - Giordania 1
LU - Lussemburgo 1
NE - Niger 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 9.275
Salva come PNG Salva come JPEG
Città #
Fairfield 838
Woodbridge 678
Santa Clara 522
Ashburn 509
Houston 476
Ann Arbor 432
Seattle 347
Chandler 307
Sofia 298
Cambridge 293
Wilmington 273
Lancaster 226
Beijing 200
New York 196
Abidjan 145
Princeton 129
Boardman 113
Lawrence 111
Medford 107
Singapore 102
Ottawa 101
Serra 98
Des Moines 90
Nanjing 61
Dong Ket 59
Istanbul 56
London 45
San Diego 43
Florence 39
Guangzhou 34
Redwood City 34
Washington 33
Dearborn 31
Vienna 26
Phoenix 25
Milan 23
Siauliai 22
Hong Kong 19
Nanchang 19
Shanghai 19
Los Angeles 18
Rome 16
Dakar 15
Kunming 14
Düsseldorf 13
Jiaxing 13
Changsha 12
Hebei 11
Shenyang 11
Chicago 10
Norwalk 10
Bremen 9
Detroit 9
Frankfurt am Main 9
Cotonou 8
Bologna 7
Fuzhou 7
Hangzhou 7
Toronto 7
Hefei 6
Jinan 6
Kent 6
Oranmore 6
Pisa 6
Berlin 5
Esslingen am Neckar 5
Guadalajara 5
Indiana 5
Adana 4
Bareggio 4
Brussels 4
Budapest 4
Cairo 4
Cuauhtémoc 4
Dallas 4
Empoli 4
Izmir 4
Mexico 4
Quanzhou 4
Quezon City 4
San Francisco 4
Shenzhen 4
Surabaya 4
Tianjin 4
Bogotá 3
Buenos Aires 3
Chapel Hill 3
Chengdu 3
Edinburgh 3
Foligno 3
Fremont 3
Haikou 3
Hanoi 3
Jakarta 3
Kaunas 3
Lima 3
Lucca 3
Montreal 3
Muizenberg 3
Napoli 3
Totale 7.547
Salva come PNG Salva come JPEG
Nome #
Trattamento topico delle dermatiti da contatto: validazione scientifica di una crema lenitiva a base di biotina, L-carnitina, pantenolo, α-bisabololo e tocoferolo. [Topical treatment of contact dermatitis with natural active principles] 199
Assessment of disease severity and treatment effectiveness in hidradenitis suppurativa 174
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 152
Sensors and Biosensors for C-Reactive Protein, Temperature and pH, and Their Applications for Monitoring Wound Healing: A Review 143
Nanomedicine in dermatology: Benefits and emerging applications 139
Potential correlation of wound bed score and biomarkers in chronic lower leg wounds: an exploratory study 134
The Quality of Life impairment in Hidradenitis Suppurativa 126
Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. 122
Complete Resolution of Erythrodermic Psoriasis in an HIV and HCV Patient Unresponsive to Antipsoriatic Treatments after Highly Active Antiretroviral Therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). 118
Deep pulse fractional CO2 laser combined with a radiofrequency system: results of a case series 116
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 116
Alexithymia affects patients with hidradenitis suppurativa 115
A new therapeutic for the treatment of moderate to severe plaque psoriasis: apremilast 114
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. 109
Optimizing acitretin use in patients with plaque psoriasis 109
Apremilast for the treatment of psoriasis 107
A revolutionary therapeutic approach for psoriasis: bispecific biological agents. 107
Risankizumab for the treatment of moderate to severe psoriasis 104
Cutaneous human papillomaviruses as recurrence factor in actinic keratoses 103
New insights in the pathogenesis of cutaneous autoimmune disorders. 103
IL-6 as a druggable target in psoriasis: Focus on pustular variants 103
Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses 102
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 102
Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy 102
Acne fulminans associated with lymecycline intake: A case report 101
Long-Term Outcome of Adalimumab in a Young Girl with Hidradenitis Suppurativa 100
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 99
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis 98
A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents 97
Gene Expression Profiling Associated with the Progression of Classic Kaposi’s Sarcoma. 96
Effective topical agents and emerging perspectives in the treatment of psoriasis. 96
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus 96
Profile of certolizumab and its potential in the treatment of psoriatic arthritis. 95
Scanning the immunopathogenesis of psoriasis 94
Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. 94
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry 94
Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. 94
Pathogenic role of IL-17 in psoriasis and psoriatic arthritis 93
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris 93
Relevance of in vitro 3-D skin models in dissecting cytokine contribution to psoriasis pathogenesis 93
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 93
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 93
Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. 92
New topical treatments for psoriasis 91
Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? 91
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. 91
UVA-1 Laser in the Treatment of Palmoplantar Pustular Psoriasis 89
Apheresis in the treatment of recalcitrant atopic dermatitis: Case series and review of the literature 89
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers. 88
Tofacitinib for the treatment of moderate-to-severe psoriasis 88
The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies. 87
Granuloma annulare: A case treated with infliximab successfully 87
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: Results of a single-centre, retrospective study 86
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 86
Lasers and Energy Devices for the Skin: Conventional and Unconventional Use 86
No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents 86
Biomarkers for psoriasis skin lesions 86
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 85
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. 84
Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis 84
Biomolecular index of therapeutic efficacy in psoriasis treated by anti-TNF alpha agents 84
IL-17 targeted therapies for psoriasis. 83
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 83
Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy 83
Gynecomastia following isotretinoin treatment: a rare endocrine side effect 83
Emerging applications of nanomedicine in dermatology 82
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 82
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 82
Trattamento topico della xerosi cutanea severa: risultati di uno studio osservazionale. [Topical treatment of severe xerosis: Results of an observational study] 81
IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model. 81
Isotretinoin-triggered acne fulminans: a rare, disabling occurrence 81
An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis 80
Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study 80
HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa 80
Efficacy and safety of Infliximab in psoriatic patients over the age of 65 79
Immunologic biomarkers for clinical and therapeutic management of psoriasis 78
PsAPASH: A new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition 78
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. 77
Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab. 76
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. 76
Unconventional Use of Intense Pulsed Light 76
A giant annular rash in a tuscanian woodman: the many faces of erythema chronicum migrans 75
Genetic Markers for Cardiovascular Disease in Psoriasis: The Missing Piece. 74
Ustekinumab for treatment of plaque psoriasis in patient with Down Syndrome. 74
Elderly psoriatic patients under biological therapies: an Italian experience 73
Use of Vitamins and their Derivates in the Treatment of Cutaneous Disorders. 70
Adipose tissue response to IL-17 combined with TNF-alpha exposure 70
The Hidradenitis Suppurativa (HS) “Multidisciplinary Unit”: a rationale and practical proposal for an organised clinical approach 70
Psoriasis 68
Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept 68
Dusky Red Swelling of the Penis in Association with Fever and Diarrhoea: A Quiz. 66
The management of moderate-to-severe chronic plaque psoriasis 66
European consensus statement on phenotypes of pustular psoriasis 66
Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study 65
Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches 63
Potential role of serum amyloid A in hidradenitis suppurativa 62
Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice 60
Diabete mellito e malattie cutanee autoimmuni 59
Un nuovo approccio fototerapico alle dermatosi croniche 58
Dermal CARD14 expression in psoriasis 56
Totale 9.162
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.721
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.721
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.182 0 0 0 0 0 229 215 198 210 150 147 33
2020/2021818 66 59 50 48 44 54 37 51 84 77 43 205
2021/20221.112 23 42 46 65 230 159 21 81 42 16 45 342
2022/20231.155 159 166 80 62 110 117 16 83 258 5 82 17
2023/2024768 36 39 90 30 110 243 20 42 6 23 14 115
2024/2025867 6 116 28 128 366 223 0 0 0 0 0 0
Totale 9.650